Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
8 evidence topics · 9 sources
Gonadotropin-releasing hormone or LHRH agonists for premenopausal women and men
“Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combination partners under study: CDK4/6, CDK4, PI3Kα, and mTOR inhibitors
Ribociclib: dosing and pharmacokinetic compatibility
Palbociclib: dosing and pharmacokinetic compatibility
Antiemetics and proton pump inhibitors
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue [26].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Colony-stimulating factors for neutropenia
Medications not permitted: QT-prolonging drugs and strong CYP3A4 inhibitors or inducers
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Washout of prior anticancer therapies
“Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone-modifying agents
No evidence found.